Webinar Date: Tuesday, February 27, 2024

Webinar Time: 11 AM EST / 8 AM PST / 5 PM CET

Register today for the upcoming BioProcess International Ask the Expert Webinar. Join the conversation to discuss using engineered devices, model predictions, metabolic screening, and molecular biology techniques. These discussions will focus on affordable and scalable vector production.

Gene therapy has the ability to revolutionize healthcare. The AAV, made using the triple-plasmid method in HEK 293 cells, is a widely used viral vector. This is because its non-pathogenic characteristics, broad range of targets, ability to modify its traits, and established production systems.

In this webinar, explore approaches to address these technological gaps. Learn more about utilizing engineered devices, model predictions, metabolic screening, and molecular biology techniques for cost-effective and scalable vector production.

Prasanna Srinivasan, PhD and Graziella Piras, PhD will present on strategies for analytical tools, to assess key nutrient composition, providing feedback to optimize feed and supplement addition strategies. Additionally, we will discuss the use of continuous culture for AAV production from the triple-plasmid transfection HEK293 system.

Key Takeaways:
  • Use of model-driven approach to design, predict, test, and optimize VV production processes.
  • Benefit of using high-throughput metabolite screening to optimize AAV production using triple transfection method.
  • Scale up and transfer to a continuous process at a bioreactor scale.